PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events

Blood

Volumn 124, Issue 4, 2014, Pages 567-578

  Mendes, Rui D ^a   Sarmento, Leonor M ^b   Canté Barrett, Kirsten ^a   Zuurbier, Linda ^a   Buijs Gladdines, Jessica G C A M ^a   Póvoa, Vanda ^b   Smits, Willem K ^a   Abecasis, Miguel ^c   Yunes, J Andres ^d   Sonneveld, Edwin ^e   Horstmann, Martin A ^f,g   Pieters, Rob ^a,h   Barata, João T ^b   Meijerink, Jules P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c Hospital Sta Cruz   (Portugal)

^d CENTRO INFANTIL BOLDRINI   (Brazil)

^e DCOG Dutch Childhood Oncology Group   (Netherlands)

^f German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h Department of Radiation Oncology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SIGNAL PEPTIDE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR TAL1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CHILDHOOD LEUKEMIA; CLONAL VARIATION; COPY NUMBER VARIATION; EXON; GENE DELETION; GENE LOCUS; GENE REARRANGEMENT; GENETIC RECOMBINATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; PRELEUKEMIA; PRIORITY JOURNAL; T CELL LEUKEMIA; THYMOCYTE; XENOTRANSPLANTATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; GENE DELETION; GENE REARRANGEMENT; HOMEODOMAIN PROTEINS; HUMANS; LIM DOMAIN PROTEINS; MICE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RECOMBINATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84904888382     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-562751     Document Type: Article

References (66)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354(2):166-178. (Pubitemid 43076714)
2. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010;23(3):307-318.
3. Dik WA, Nadel B, Przybylski GK, et al. Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood. 2007;110(1): 388-392. (Pubitemid 47026860)
4. Le Noir S, Ben Abdelali R, Lelorch M, et al. Extensive molecular mapping of TCRα/δ- and TCRβ-involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL. Blood. 2012;120(16): 3298-3309.
5. Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites. J Exp Med. 2002; 195(1):85-98. (Pubitemid 34074499)
6. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497.
7. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271. (Pubitemid 39336870)
8. Sulis ML, Williams O, Palomero T, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112(3):733-740.
9. Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007; 67(12):5611-5616. (Pubitemid 46984990)
10. published correction appears in Cancer Res. 2008;15;68(6):2051.
11. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813-1824. (Pubitemid 47236319)
12. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007; 204(8):1825-1835. (Pubitemid 47236320)
13. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology (Am Soc Hematol Educ Program). 2009;353-361.
14. Shochat C, Tal N, Bandapalli OR, et al. Gain-offunction mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208(5):901-908.
15. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011; 43(10):932-939.
16. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007; 13(10):1203-1210. (Pubitemid 47530629)
17. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
18. Jotta PY, Ganazza MA, Silva A, et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia. 2010;24(1):239-242.
19. Zuurbier L, Petricoin EF III, Vuerhard MJ, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97(9):1405-1413.
20. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7(8):965-970. (Pubitemid 351679827)
21. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007;447(7147):966-971. (Pubitemid 46975753)
22. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454-458.
23. Correia NC, Gírio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2014;50(1):216-225.
24. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 2011;476(7359):163-169.
25. Silva A, Yunes JA, Cardoso BA, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118(11): 3762-3774.
26. Kamps WA, Bökkerink JP, Hählen K, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood. 1999;94(4):1226-1236. (Pubitemid 29380403)
27. Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002;16(6):1099-1111. (Pubitemid 34624558)
28. Veerman AJ, Kamps WA, van den Berg H, et al; Dutch Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10(10):957-966.
29. Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE; COALL study group. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82, 85, 89, 92 and 97. Leukemia. 2010;24(2):298-308.
30. Trancoso I, Bonnet M, Gardner R, et al. A novel quantitative fluorescent reporter assay for RAG targets and RAG activity. Front Immunol. 2013;4: 110.
31. Cowell LG, Davila M, Kepler TB, Kelsoe G. Identification and utilization of arbitrary correlations in models of recombination signal sequences. Genome Biol. 2002;3(12): RESEARCH0072.
32. Gellert M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem. 2002;71(1):101-132. (Pubitemid 34800216)
33. Lewis SM, Agard E, Suh S, Czyzyk L. Cryptic signals and the fidelity of V(D)J joining. Mol Cell Biol. 1997;17(6):3125-3136. (Pubitemid 27215027)
34. Raghavan SC, Kirsch IR, Lieber MR. Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints. J Biol Chem. 2001;276(31):29126-29133.
35. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4): 653-661.
36. Zuurbier L, Homminga I, Calvert V, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014-2022.
37. Bandapalli OR, Zimmermann M, Kox C, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica. 2013;98(6):928-936.
38. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTENbased oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31(34):4333-4342.
39. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2009;23(8):1417-1425.
40. Marculescu R, Le T, Böcskör S, et al. Alternative end-joining in follicular lymphomas' t(14;18) translocation. Leukemia. 2002;16(1):120-126. (Pubitemid 34105607)
41. Papaemmanuil E, Rapado I, Li Y, et al. RAGmediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014; 46(2):116-125.
42. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science. 1990;250(4986):1426-1429. (Pubitemid 120031866)
43. Larmonie NS, Dik WA, Meijerink JP, Homminga I, van Dongen JJ, Langerak AW. Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia. Haematologica. 2013; 98(8):1173-1184.
44. Radich J, Sala O. The biology of adult acute lymphoblastic leukemia. In: Advani AS, Lazarus HM, eds. Adult Acute Lymphocytic Leukemia. New York, NY: Humana Press; 2011:25-44.
45. Mullighan CG, Miller CB, Radtke I, et al. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191): 110-114. (Pubitemid 351630327)
46. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10): 2159-2167.
47. Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion (ERG) is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70-77.
48. Waanders E, Scheijen B, van der Meer LT, et al. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet. 2012;8(2):e1002533.
49. Raschke S, Balz V, Efferth T, Schulz WA, Florl AR. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer. 2005;42(1):58-67. (Pubitemid 39578665)
50. Novara F, Beri S, Bernardo ME, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 2009;126(4):511-520.
51. Kitagawa Y, Inoue K, Sasaki S, et al. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem. 2002;277(48):46289-46297. (Pubitemid 35417622)
52. Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood. 2010;116(25):5455-5464.
53. Tsuji H, Ishii-Ohba H, Katsube T, et al. Involvement of illegitimate V(D)J recombination or microhomology-mediated nonhomologous endjoining in the formation of intragenic deletions of the Notch1 gene in mouse thymic lymphomas. Cancer Res. 2004;64(24):8882-8890. (Pubitemid 39665493)
54. Sakata J, Inoue J, Ohi H, et al. Involvement of V(D)J recombinase in the generation of intragenic deletions in the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic lymphomas and in normal thymus of the mouse. Carcinogenesis. 2004;25(6):1069-1075. (Pubitemid 38886089)
55. Grawunder U, Harfst E. How to make ends meet in V(D)J recombination. Curr Opin Immunol. 2001; 13(2):186-194. (Pubitemid 32176038)
56. Lee J, Desiderio S. Cyclin A/CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair. Immunity. 1999; 11(6):771-781. (Pubitemid 30030716)
57. Baer R, Forster A, Rabbitts TH. The mechanism of chromosome 14 inversion in a human T cell lymphoma. Cell. 1987;50(1):97-105. (Pubitemid 18098335)
58. Arnal SM, Holub AJ, Salus SS, Roth DB. Non-consensus heptamer sequences destabilize the RAG post-cleavage complex, making ends available to alternative DNA repair pathways. Nucleic Acids Res. 2010;38(9):2944-2954.
59. Lewis SM, Hesse JE, Mizuuchi K, Gellert M. Novel strand exchanges in V(D)J recombination. Cell. 1988;55(6):1099-1107. (Pubitemid 19020062)
60. Elliott JF, Rock EP, Patten PA, Davis MM, Chien YH. The adult T-cell receptor delta-chain is diverse and distinct from that of fetal thymocytes. Nature. 1988;331(6157):627-631. (Pubitemid 18049529)
61. Davila M, Liu F, Cowell LG, et al. Multiple, conserved cryptic recombination signals in VH gene segments: detection of cleavage products only in pro B cells. J Exp Med. 2007;204(13): 3195-3208.
62. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330): 356-361.
63. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008; 322(5906):1377-1380. (Pubitemid 352775249)
64. Yang JJ, Bhojwani D, Yang W, et al. Genomewide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008; 112(10):4178-4183.
65. Kuster L, Grausenburger R, Fuka G, et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117(9):2658-2667.
66. Marculescu R, Vanura K, Le T, Simon P, Jäger U, Nadel B. Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and individuals with T-ALL. Nat Genet. 2003;33(3):342-344. (Pubitemid 36278849) a Tecnologia